SCLX Profile
Scilex Holding Company is a biopharmaceutical firm dedicated to the development and commercialization of non-opioid products designed to manage both acute and chronic pain. Its flagship commercial product, ZTlido 1.8%, is a prescription lidocaine topical system aimed at alleviating neuropathic pain associated with post-herpetic neuralgia, a condition resulting from shingles. This product is part of Scilex's broader mission to offer alternatives to opioid-based pain management therapies.
In addition to ZTlido, Scilex is advancing several pipeline products targeting various pain management needs. SP-102, a viscous gel formulation of corticosteroid, is undergoing Phase III clinical trials for its efficacy in treating lumbosacral radicular pain, a type of nerve pain originating from the lower back. SP-103, currently in Phase II clinical trials, is focused on addressing low back pain, a common and challenging condition affecting many individuals.
The company is also exploring innovative treatments with SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trials for the management of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain. These developments reflect Scilex's commitment to expanding its portfolio of non-opioid pain management solutions and addressing unmet medical needs in the pain management market.
Headquartered in Palo Alto, California, Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc. The company leverages its position within the larger Sorrento ecosystem to drive innovation and bring advanced therapeutic options to market. With a focus on developing cutting-edge treatments and improving patient outcomes, Scilex is poised to make significant contributions to the field of pain management.
|
